OPMIZTA Trademark

Trademark Overview

On Friday, July 2, 2021, a trademark application was filed for OPMIZTA with the United States Patent and Trademark Office. The USPTO has given the OPMIZTA trademark a serial number of 90808336. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Thursday, June 6, 2024. This trademark is owned by PhaseBio Pharmaceuticals, Inc.. The OPMIZTA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
opmizta

General Information

Serial Number90808336
Word MarkOPMIZTA
Filing DateFriday, July 2, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateThursday, June 6, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 26, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 13, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSFJ PHARMA X, INC.
Party Type22 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressPleasanton, CA 94588
Party NameSFJ PHARMACEUTICALS X, LTD.
Party Type21 - New Owner After Publication
Legal Entity Type11 - Company
AddressPleasanton, CA 94588
Party NamePhaseBio Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMalvern, PA 19355
Party NamePhaseBio Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMalvern, PA 19355

Trademark Events

Event DateEvent Description
Tuesday, July 6, 2021NEW APPLICATION ENTERED
Monday, September 13, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 23, 2022ASSIGNED TO EXAMINER
Wednesday, March 23, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 6, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 26, 2022PUBLISHED FOR OPPOSITION
Tuesday, April 26, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 21, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 12, 2022SOU TEAS EXTENSION RECEIVED
Monday, December 12, 2022SOU EXTENSION 1 FILED
Monday, December 12, 2022SOU EXTENSION 1 GRANTED
Wednesday, December 14, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 8, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, April 18, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Tuesday, April 18, 2023WITHDRAWAL OF ATTORNEY GRANTED
Wednesday, June 21, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, June 21, 2023SOU EXTENSION 2 FILED
Wednesday, June 21, 2023SOU EXTENSION 2 GRANTED
Friday, June 23, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 21, 2023SOU TEAS EXTENSION RECEIVED
Thursday, December 21, 2023SOU EXTENSION 3 FILED
Tuesday, January 2, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, January 2, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 2, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, January 10, 2024AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, January 12, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, January 12, 2024SOU EXTENSION 3 GRANTED
Saturday, January 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 6, 2024SOU TEAS EXTENSION RECEIVED
Thursday, June 6, 2024SOU EXTENSION 4 GRANTED
Thursday, June 6, 2024SOU EXTENSION 4 FILED
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

opmizta ticagrelor activity antiplatelet reverse major bleeding situations surgery urgent designed